Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors

A method for treating obesity, type 2 diabetes mellitus, and/or insulin resistance, the method comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I)

• wherein
• X is CH or N;
• R1 is selected from the group consisting of CH3—CH2OH CH3, —CH2OH and Cl;
• R2 is independently of each other selected from the group consisting of H, F, Cl, Br, I, CN, C1-6-alkyl, C3-7-cycloalkyl, OH, —O—(C1-6-alkyl), —O—(C3-7-cycloalkyl), —O—(C1-3-alkyl)-(C3-7-cyclo alkyl) —O—(C1-3-alkyl)-(C3-7-cycloalkyl), —O-heterocyclyl, —O—(C1-3-alkyl)-heterocyclyl, —O-aryl, —O-heteroaryl, —S—(C1-3-alkyl), —SO—(C1-3-alkyl), —SO21-3-alkyl) —SO2-(C1-3alkyl), —NH2, —NH—(C1-6-alkyl), —NH—(C3-6-cycloalkyl), —NH—(C1-3-alkyl)-heterocyclyl, —NH—(C1-6-alkyl-C(═O)—NH2—C(═O)—NH2—C(═O)—NH—(C1-3-alkyl) —NH—(C1-6-alkyl)-C(═O)—NH2, —C(═O)—NH2, —C(═O)—NH—(C1-3-alkyl), —C(═O)—N(C1-3-alkyl)2, —C(═O)OH, —C(═O)—O—(C1-4-alkyl), —C(═O)—(C1-4-alkyl), alkyl) —C1-3-alkyl-C(═O)—O—(C1-4-alkyl), heterocyclyl, heteroaryl and 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl,
• wherein each alkyl or cycloalkyl group is optionally independently substituted with one or more substituents selected from the group consisting of F, CN and OH, and
• wherein each heterocyclyl group is selected from the group consisting of a mono- or spirocyclic 4-7-membered cycloalkyl group, in which 1, 2 or 3 CH2-groups are independently of each other replaced by O, S, NH or C═O, and
• wherein each heterocyclyl group is optionally substituted with 1 or 2 substituents independently of each other selected from the group consisting of F, OH and C1-3-alkyl,
• wherein each aryl group is selected from the group consisting of phenyl and naphthyl, and
• wherein each heteroaryl group is selected from the group consisting of a 5-membered aromatic cycle containing 1 or 2 heteroatoms independently selected from the group consisting of N, O and S or from a 6-membered aromatic cycle containing 1 or 2 N, and
• wherein each aryl or heteroaryl group is optionally substituted with 1 or 2 substituents independently selected from the group consisting of F, CN and C1-3-alkyl, which is optionally substituted with one or more F;
• or, if two groups R2 are attached to adjacent C atoms of the pyridine or pyrimidine group, they may be linked with each other and together form a O—CH2—O— —O—CH2—O—, —O—CH2—CH2—O— or —O—CH2—CH2—CH2—O— bridge, in which 1 or 2H 2 H atoms may be replaced with F or C1-3-alkyl;
• and
• n is 1, 2 or 3;
• wherein each of the above-mentioned alkyl groups may be substituted with one or more F;
• or a pharmaceutically acceptable salt thereof.